Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development and manufacture of therapeutic proteins and antibodies, and it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its partners.

Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group’s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics, Antitope, PacificGMP and TCRS.

PolyTherics, Antitope, PacificGMP and TCRS have been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.

Type
Public
HQ
Cambridgeshire, GB
Founded
2002
Size (employees)
91 (est)+153%
Abzena was founded in 2002 and is headquartered in Cambridgeshire, GB

Key People at Abzena

John Burt

John Burt

CEO
Julian Smith

Julian Smith

CFO
Matthew Baker

Matthew Baker

CSO

Abzena Office Locations

Abzena has offices in Cambridgeshire, Bristol, Coventry, San Diego
Cambridgeshire, GB
Bristol, US
Coventry, GB
San Diego, US

Abzena Metrics

Abzena Summary

Market capitalization

£51.4 M

Closing share price

£0.395
Abzena's current market capitalization is £51.4 M.

Abzena Financials

Abzena's revenue is £9.85 M in FY, 2016 which is 73.88% increase from the previous period.
FY, 2016FY, 2015FY, 2014

Revenue

£9.85 M£5.67 M£5.26 M

Revenue growth, %

73.9%7.7%

Cost of sales

£5.32 M£2.53 M£1.7 M

Gross profit

£4.54 M£3.14 M£3.56 M

Gross profit Margin, %

46.0%55.3%67.7%

Operating expense total

£15.4 M£8.43 M£7.69 M

Abzena Market Value History

We estimate that Abzena's current employees are approximately 35% female and 65% male.

Abzena Online Presence

Abzena Company Life

You may also be interested in